Literature DB >> 2006023

Neopterin in cerebrospinal fluid: a useful marker for diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis.

M Nomoto1, Y Utatsu, Y Soejima, M Osame.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2006023     DOI： 10.1212/wnl.41.3.457

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

1.  HTLV-I-associated myelopathy: are ferritin, S100beta protein, or guanine nucleotides CSF markers of disease?

Authors:  Andrea Regner; Ottomar Bianchini; Claudio Jardim; Marcio Menna-Barreto
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

Review 2.  T helper cell activation and human retroviral pathogenesis.

Authors:  K F Copeland; J L Heeney
Journal:  Microbiol Rev       Date:  1996-12

3.  Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Mineki Saito; Reiko Tanaka; Shiho Arishima; Toshio Matsuzaki; Satoshi Ishihara; Takashi Tokashiki; Yusuke Ohya; Hiroshi Takashima; Fujio Umehara; Shuji Izumo; Yuetsu Tanaka
Journal:  Retrovirology       Date:  2013-05-07       Impact factor: 4.602

4.  CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Tomoo Sato; Ariella Coler-Reilly; Atae Utsunomiya; Natsumi Araya; Naoko Yagishita; Hitoshi Ando; Junji Yamauchi; Eisuke Inoue; Takahiko Ueno; Yasuhiro Hasegawa; Kusuki Nishioka; Toshihiro Nakajima; Steven Jacobson; Shuji Izumo; Yoshihisa Yamano
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10

5.  The CC chemokine ligand (CCL) 1, upregulated by the viral transactivator Tax, can be downregulated by minocycline: possible implications for long-term treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Mineki Saito; Hiroe Sejima; Tadasuke Naito; Hiroshi Ushirogawa; Toshio Matsuzaki; Eiji Matsuura; Yuetsu Tanaka; Tatsufumi Nakamura; Hiroshi Takashima
Journal:  Virol J       Date:  2017-12-04       Impact factor: 4.099

6.  Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.

Authors:  Massanobu Takatani; Myuki Esashika Crispim; Nelson Fraiji; Mariane Martins Araujo Stefani; Dagmar Kiesslich
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

7.  Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

Authors:  Keiko Tamaki; Tomoo Sato; Jun Tsugawa; Shinsuke Fujioka; Naoko Yagishita; Natsumi Araya; Junji Yamauchi; Ariella L G Coler-Reilly; Misako Nagasaka; Yasuhiro Hasegawa; Yoshihisa Yamano; Yoshio Tsuboi
Journal:  Front Microbiol       Date:  2019-09-11       Impact factor: 5.640

8.  In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Mineki Saito; Toshio Matsuzaki; Yorifumi Satou; Jun-Ichirou Yasunaga; Kousuke Saito; Kimiyoshi Arimura; Masao Matsuoka; Yoshiro Ohara
Journal:  Retrovirology       Date:  2009-02-19       Impact factor: 4.602

9.  Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.

Authors:  Yoshihisa Yamano; Natsumi Araya; Tomoo Sato; Atae Utsunomiya; Kazuko Azakami; Daisuke Hasegawa; Toshihiko Izumi; Hidetoshi Fujita; Satoko Aratani; Naoko Yagishita; Ryoji Fujii; Kusuki Nishioka; Steven Jacobson; Toshihiro Nakajima
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

Review 10.  Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Retrovirology       Date:  2019-11-29       Impact factor: 4.602
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.